Our Team

FOUNDER & CEO

John’s career began in electrical engineering, which he parlayed into a career as an intellectual property attorney representing Silicon Valley tech clients. For over two decades, John practiced IP law in a Silicon Valley law firm he founded and managed, primarily focusing on patent portfolio development and analysis involving deep tech inventions. John's interest in the aging field, which began almost 20 years ago, led to research, both basic and translational, into the biology of aging. Using a multidisciplinary approach, John founded AgeisBio and evaluated a target pathway to address aging itself. He currently focuses on preclinical drug development.

Scientific Advisor

A molecular and cellular biologist, Aditi has extensive expertise in inflammatory signaling, genomic instability and the development of processes and procedures for laboratory investigation of complex cellular biology. Her research includes the elucidation of a novel link between the NF-kappa-B signaling and genomic instability leading to oncogenesis and cellular transformation. Aditi directs laboratory operations for AgeisBio’s research.

COMPUTATIONAL & MEDICINAL CHEMIST

Dale is a consultant and owner of West Coast Chemistry Services in Vancouver, BC. Dale has a history of accelerating drug design projects by combining traditional medicinal chemistry methods with tools at the interface between theory and experiment. Dale possesses a mix of structural research skills using NMR, X-ray and Cryo-EM data combined with computational chemistry. In our connected world, these interdisciplinary aspects can all be performed well in a “virtual” mode, thereby limiting infrastructure challenges while leveraging the broad skill sets needed to succeed.

VP, BUSINESS DEVELOPMENT & STRATEGIC PARTNERSHIPS

Stephanie brings extensive experience in biopharmaceuticals and has held diverse leadership roles in Alliance Management, International Expansion, Marketing, and Sales in the US and Asia with leading companies such as Puma Biotechnology, Amgen, Boehringer Ingelheim, and DKSH. Stephanie began her career in Sales and was subsequently promoted to Market Research at Boehringer Ingelheim, supporting brands in the US. She then joined Amgen in Global Marketing and Market Research, where she executed projects delivering commercial inputs for early and late-stage products in Nephrology and Inflammation therapeutic areas. Most recently, she led Global Alliances at Puma Biotechnology, driving successful collaborations that led to the approval and launch of Nerlynx, a HER2+ breast cancer treatment, in various international markets. Stephanie currently focuses on business development and establishing strategic partnerships for AgeisBio.